Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, induce a protective tumor-specific response
Autore:
Rescigno, M; Valzasina, B; Bonasio, R; Urbano, M; Ricciardi-Castagnoli, P;
Indirizzi:
Univ Milan, Dept Biotechnol & Biosci, I-20126 Milan, Italy Univ Milan Milan Italy I-20126 Biotechnol & Biosci, I-20126 Milan, Italy
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 3, volume: 7, anno: 2001, supplemento:, S
pagine: 865S - 870S
SICI:
1078-0432(200103)7:3<865S:DCLWRB>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
THERAPEUTIC ANTITUMOR IMMUNITY; CYTOTOXIC T-LYMPHOCYTES; IN-VIVO; PEPTIDE; MATURATION; VACCINATION; MELANOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Ricciardi-Castagnoli, P Univ Milan, Dept Biotechnol & Biosci, I-20129 Milan, Italy Univ Milan Milan Italy I-20129 0129 Milan, Italy
Citazione:
M. Rescigno et al., "Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, induce a protective tumor-specific response", CLIN CANC R, 7(3), 2001, pp. 865S-870S

Abstract

Dendritic cells (DCs) are considered the most potent antigen-presenting cells and probably the only ones able to prime naive T cells, Indeed, DCs aredistributed in tissues that interface the external environment, where theyact as sentinels for incoming bacteria, viruses, and fungi, We have previously analyzed the capacity of DCs to interact with bacteria, and we have shown that bacteria can act as "Trojan horses," delivering heterologous proteins to DCs in a processed form that allows extremely efficient loading of both MHC class I and class II molecules, In this study, we have optimized the usage of recombinant bacteria as an antigen delivery system for DCs, withthe aim to develop a new DC vaccination strategy in antitumor immunity. Wehave focused on a low immunogenic antigen, the tyrosinase-related protein-2 (Trp-2), a self-antigen expressed in mouse and human melanoma for which induction of antitumor immunity has proven to be very ineffective. We have given mice injections of either Trp-2/recombinant bacteria-loaded DCs or with bacteria alone engineered to express the Trp-2 melanoma antigen. We have shown that only DCs loaded with recombinant bacteria, but not with wild-type bacteria, were able to induce Trp-2-specific CTLs and immunity against the B16 tumor, Immunity was obtained in experiments of tumor vaccination as well as in experiments of tumor therapy. When therapy with bacteria-loaded DCs was performed in B16 tumor-bearing mice, 60% of the treated mice were tumor free 2 months after the initial tumor growth.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/04/20 alle ore 11:59:02